The AKR1D1 antibody is a crucial tool for studying the aldo-keto reductase family 1 member D1 (AKR1D1), a liver-enriched enzyme involved in steroid and bile acid metabolism. AKR1D1. also known as 5β-reductase, catalyzes the reduction of Δ?-3-ketosteroids to 5β-dihydrosteroids, a rate-limiting step in bile acid synthesis and steroid hormone inactivation. This enzyme plays a pivotal role in regulating hormonal balance, cholesterol homeostasis, and detoxification processes. Dysregulation of AKR1D1 has been linked to cholestasis, metabolic disorders, and hormone-sensitive cancers.
AKR1D1 antibodies are widely used in research to detect protein expression, localization, and quantification via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They aid in investigating AKR1D1’s physiological roles, its interaction with substrates, and its implications in diseases. Commercial antibodies are typically raised against specific epitopes, such as human AKR1D1’s C-terminal region, and validated for species cross-reactivity. Challenges include ensuring specificity due to structural similarities within the AKR1D subfamily. Recent studies highlight AKR1D1’s therapeutic potential, driving demand for reliable antibodies to explore its regulatory mechanisms and develop targeted treatments.